EGFR and neoplasm: In contrast, EGFR affinity-reduced DuetMabs and in particular variants VκS93A + VHP97A and VκF94A + VHP97A, mediated a significant degree of selective tumor targeting (P < 0.014 and P < 0.003, respectively), as evidenced by preferential eradication of the double-positive over the single-positive tumors.